As compared with T2D group, more patients in DKD group take angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB) or SGLT2 inhibitor. This evidence concerns the gene SLC5A2 and diabetic kidney disease.